IDO1 and myeloid sarcoma: It’s known, that increased IDO-1 activity suppress the T-cell mediated immune response in MS (Mellor and Munn, 2004; Mancuso et al., 2015), via activation of aryl hydrocarbon receptor (AhR) (Bessede et al., 2014).